Skip to main content

Pharma companies team up with DeSci to accelerate scientific research

Pfizer is now the first big pharma to participate in a decentralized autonomous organization (DAO).

Having emerged as a movement in the research community, Decentralized Science (DeSci) initiatives are progressing at a pace even big pharma cannot ignore. In fact, Pfizer is now the first pharmaceutical to vote on decentralized autonomous organization (DAO) proposals of German blockchain-based organization VitaDAO.

The collaboration is part of VitaDAO's latest fundraising disclosed in late January from strategic members, including Pfizer Ventures, Shine Capital and L1 Digital, among other longevity enthusiasts. The $4.1 million raised will be used to fund longevity research projects and accelerate the spinout of VitaDAO's first biotech startups, with two more in development for 2023.

"Pfizer is now bringing some of their own scientists to join with the community of researchers who are part of VitaDAO to help incubate some of this research," told Cointelegraph Alex Dobrin, community and awareness steward at VitaDAO.

DeSci has fostered the emergence of a thriving ecosystem with projects ranging from decentralized biotech foundations to funding vehicles. "Some of the major trends in the field can include research & investment platforms, crowdfunding for scientific research, scientists and researcher communities," explained Dr. Tuan Cao, founder of GenomicDAO, a San Francisco-based platform launched on Feb. 19 by AI biotech company Genetica.

This decentralized platform aims to establish a community to drive and govern Asian-focused precision medicine initiatives. Its first subsidiary DAO is working on stroke prevention, targeting awareness and R&D for ischemic strokes.

Worldwide, stroke is one of the most common causes of disability and vascular death. The American Heart Association reports that there were over 77 million ischemic strokes around the world in 2019. Asian populations have higher stroke incidences than Western populations, according to a study published in the Journal of clinical hypertension in 2021.

GenomicDAO claims that the combination of a network of research groups, institutions, organizations, scientists and medical experts with artificial intelligence can reduce time to release a new product from 12–18 months to 4–6 months. According to GenomicDAO, community-driven initiatives are disrupting scientific research:

"In the precision medicine space, R&D is led by a handful of big names in the industry that are de-facto monopolizing the market. Monopolistic and centralized pharmaceutical companies equivalently lead to the stagnation of innovation; simultaneously widening the gap in providing precision medicine to underrepresented populations."

Comments

Post a Comment

Popular posts from this blog

BTC hodlers outperformed crypto funds by 69% in H1: 21e6 Capital

Image
21e6 Capital AG stated that crypto funds generally outperformed the price gains of BTC in previous bull runs, but ultimately suffered this year from having too much cash on hand and playing it safe. The classic buy and hold, or HODL approach to Bitcoin (BTC) out perform ed the majority of crypto funds by 68.8% in the first half (H1) of 2023. According to data from Switzerland-based investment adviser 21e6 Capital AG, on average, crypto funds generated returns of 15.2% in the first half of 2023 (Jan.1 to June 30) , compared to the roughly 84% price gain BTC saw in the same period. Crypto funds on average generated 15.2% return in the first half of 2023 lol pic.twitter.com/vb8pwYfiX9 — Alex Krüger (@krugermacro) August 5, 2023 Emphasizing the significance of such via an Aug. 2 half-year report, 21e6 Capital AG’s head of marketing Maximilian Bruckner outlined that crypto funds have been “frequently able to significantly outperform Bitcoin in previous bull runs.” Bruckner attrib...
Read more

Shiba Inu lead developer queries Coinbase's 'Onchain Summer' campaign

Kusama responded to Coinbase’s CEO, Brian Armstrong's update with the statement, "If it isn't a shadowcat, it's a copycat." Shytoshi Kusama, the lead developer of Shiba Inu, has given a response to Coinbase's Onchain Summer campaign . He suggested that Coinbase's campaign seemed to have similarities with the ideas originally presented by the Shiba Inu community. Kusama responded to Coinbase’s CEO, Brian Armstrong's update with the statement, "If it isn't a shadowcat, it's a copycat." On August 3, Armstrong showcased in a tweet the use of the Base bridge, launched the previous day, while highlighting Coinbase's upcoming Onchain Summer initiative. Coinbase is preparing to launch its Ethereum Layer 2 solution, known as Base, on the mainnet. Armstrong recently confirmed that Base is aimed at bringing the next billion users into the blockchain ecosystem. It aims to achieve this goal by offering tools for the development of various W...
Read more

Blackrock CEO issues dire warning over ‘debt ceiling drama’ — Bullish for Bitcoin?

Image
The debt ceiling has been raised but Larry Fink says trust in the U.S. dollar is being eroded, which could be good news for Bitcoin. Blackrock CEO Laurence Fink believes the recent " drama " around the United States debt ceiling has deteriorated global trust in the U.S. dollar, something that other analysts predict could provide some tailwinds for Bitcoin (BTC). Fink’s comments come as U.S. lawmakers passed a highly-anticipated bill to lift the $31.4 trillion debt ceiling on June 1. The U.S. Treasury indicated that the deadline for raising the debt ceiling was June 5. Any later, the country could begin defaulting on its debts. 314-117: The House passes the Biden-McCarthy debt ceiling agreement, raising the debt limit until 2025 and instituting discretionary spending caps for two years. 71 Republicans and 46 Democrats voted “no” on the bill. pic.twitter.com/RdU42whDd5 — The Recount (@therecount) June 1, 2023 According to a May 31 report from Reuters, Fink told the attendee...
Read more